###begin article-title 0
###xml 28 33 28 33 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 47 54 47 54 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
Lack of association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity and related metabolic phenotypes in a Danish large-scale study: case-control studies and analyses of quantitative traits
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
###xml 109 114 109 114 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 153 160 153 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 360 365 360 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 395 402 395 402 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
Several studies in multiple ethnicities have reported linkage to type 2 diabetes on chromosome 1q21-25. Both PKLR encoding the liver pyruvate kinase and NOS1AP encoding the nitric oxide synthase 1 (neuronal) adaptor protein (CAPON) are positioned within this chromosomal region and are thus positional candidates for the observed linkage peak. The C-allele of PKLR rs3020781 and the T-allele of NOS1AP rs7538490 are reported to strongly associate with type 2 diabetes in various European-descent populations comprising a total of 2,198 individuals with a combined odds ratio (OR) of 1.33 [1.16-1.54] and 1.53 [1.28-1.81], respectively. Our aim was to validate these findings by investigating the impact of the two variants on type 2 diabetes and related quantitative metabolic phenotypes in a large study sample of Danes. Further, we intended to expand the analyses by examining the effect of the variants in relation to overweight and obesity.
###end p 3
###begin title 4
Methods
###end title 4
###begin p 5
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 288 289 288 289 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 289 294 289 294 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 289 294 289 294 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PKLR </italic></sub>
###xml 303 304 303 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 304 311 304 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 304 311 304 311 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NOS1AP </italic></sub>
###xml 354 355 354 355 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 355 360 355 360 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 355 360 355 360 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PKLR </italic></sub>
###xml 369 370 369 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 370 377 370 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 370 377 370 377 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NOS1AP </italic></sub>
###xml 447 448 447 448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 448 453 448 453 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 448 453 448 453 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PKLR </italic></sub>
###xml 460 461 460 461 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 461 468 461 468 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 461 468 461 468 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NOS1AP </italic></sub>
###xml 551 552 551 552 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 552 557 552 557 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 552 557 552 557 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PKLR </italic></sub>
###xml 566 567 566 567 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 567 574 567 574 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 567 574 567 574 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NOS1AP </italic></sub>
###xml 187 199 <span type="species:ncbi:9606">participants</span>
###xml 339 346 <span type="species:ncbi:9606">patient</span>
PKLR rs3020781 and NOS1AP rs7538490 were genotyped, using TaqMan allelic discrimination, in a combined study sample comprising a total of 16,801 and 16,913 individuals, respectively. The participants were ascertained from four different study groups; the population-based Inter99 cohort (nPKLR = 5,962, nNOS1AP = 6,008), a type 2 diabetic patient group (nPKLR = 1,873, nNOS1AP = 1,874) from Steno Diabetes Center, a population-based study sample (nPKLR = 599, nNOS1AP = 596) from Steno Diabetes Center and the ADDITION Denmark screening study cohort (nPKLR = 8,367, nNOS1AP = 8,435).
###end p 5
###begin title 6
Results
###end title 6
###begin p 7
###xml 202 203 202 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 203 206 203 206 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AF </sub>
###xml 248 249 248 249 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 249 252 249 252 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AF </sub>
###xml 362 367 362 367 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 375 382 375 382 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
In case-control studies we evaluated the potential association between rs3020781 and rs7538490 and type 2 diabetes and obesity. No significant associations were observed for type 2 diabetes (rs3020781: pAF = 0.49, OR = 1.02 [0.96-1.10]; rs7538490: pAF = 0.84, OR = 0.99 [0.93-1.06]). Neither did we show association with overweight or obesity. Additionally, the PKLR and the NOS1AP genotypes were demonstrated not to have a major influence on diabetes-related quantitative metabolic phenotypes.
###end p 7
###begin title 8
Conclusion
###end title 8
###begin p 9
###xml 56 61 56 61 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 75 82 75 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
We failed to provide evidence of an association between PKLR rs3020781 and NOS1AP rs7538490 and type 2 diabetes, overweight, obesity or related quantitative metabolic phenotypes in large-scale studies of Danes.
###end p 9
###begin title 10
Background
###end title 10
###begin p 11
###xml 270 271 267 268 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
Type 2 diabetes (T2D) is a complex metabolic disease, where several tissues and organs, including pancreatic beta-cells, skeletal muscle, adipose tissue, liver and the central nervous system have been suggested to be directly or indirectly involved in the pathogenesis [1].
###end p 11
###begin p 12
###xml 120 121 120 121 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 122 124 122 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 176 183 176 183 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 496 501 496 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 604 606 601 603 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 711 713 708 710 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 797 802 790 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 918 920 911 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 921 923 914 916 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 933 938 926 931 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 1171 1173 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 815 823 <span type="species:ncbi:9606">patients</span>
Several independent studies have shown evidence for linkage between chromosome 1q21-25 and T2D in multiple ethnicities [2-14]. Both PKLR encoding the liver pyruvate kinase and NOS1AP encoding the nitric oxide synthase 1 (neuronal) adaptor protein (CAPON), are located in the 1q21-25 region and are therefore positional candidate genes for T2D susceptibility. The puryvate kinase enzyme catalyses the last step in glycolysis converting phosphoenolpyruvate to pyruvate under the generation of ATP. PKLR is, in addition to the liver, expressed in pancreatic beta-cells, the kidneys and the small intestine [15], and its expression is upregulated by glucose through a carbohydrate response element in the promoter [16]. Moreover, a binding site for hepatocyte nuclear factor 1-alpha is located in the PKLR promoter and patients with maturity-onset diabetes of the young type 1 and 3 show decreased expression of the gene [17,18]. Hence, PKLR is a strong biological candidate gene for impaired blood glucose regulation and thus T2D. The CAPON protein binds nitric oxide synthase, which results in downregulation of N-methyl-D-aspartate receptor-mediated glutamate signalling [19], however, the link between dysfunctional CAPON protein and T2D is as yet unexplained.
###end p 12
###begin p 13
###xml 187 188 187 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
A substantial number of genes, in this very gene-dense 1q21-25 region, have already been investigated for susceptibility to T2D, however, none have so far explained the observed linkage [1]. As a part of The International Type 2 Diabetes 1q Consortium 5,285 single-nucleotide polymorphisms (SNPs), covering 22.7 Mb of the 1q linkage region were genotyped in 1,000 cases and 1,198 matched controls from four different European-descent populations.
###end p 13
###begin p 14
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 45 52 45 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 212 214 212 214 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 220 222 220 222 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 268 275 268 275 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 337 339 337 339 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 345 347 345 347 <sup xmlns:xlink="http://www.w3.org/1999/xlink">-6</sup>
###xml 349 351 349 351 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 354 359 354 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 567 569 567 569 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 628 635 628 635 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
Two SNPs, rs3020781 in PKLR and rs7538490 in NOS1AP were reported to associate with T2D. Applying an additive model the C-allele of PKLR rs3020781 associated with T2D with an odds ratio (OR) of 1.33 [1.16-1.54] (p = 1.10-6), and under a dominant model the T-allele of NOS1AP rs7538490 associated with T2D with an OR of 1.53 [1.28-1.81] (p = 2.10-6)[38]. PKLR has previously been examined in two independent studies, where four SNPs, (rs3020781, rs2071053, rs1052176, rs1052177), showed association with T2D when analysing a total 909 individuals of European descent [20,21]. No further association studies regarding the role of NOS1AP in T2D pathogenesis have been performed.
###end p 14
###begin p 15
###xml 64 69 64 69 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 83 90 83 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
The aim of the present study was to validate the association of PKLR rs3020781 and NOS1AP rs7538490 with T2D. In addition we intend to expand with analyses of overweight and obesity and the relationship with diabetes-related metabolic quantitative phenotypes.
###end p 15
###begin title 16
Methods
###end title 16
###begin title 17
Subjects
###end title 17
###begin p 18
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 214 215 214 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 215 220 215 220 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 215 220 215 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PKLR </italic></sub>
###xml 229 230 229 230 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 230 237 230 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 230 237 230 237 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NOS1AP </italic></sub>
###xml 320 321 316 317 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 381 383 377 379 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 412 413 408 409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 413 418 409 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 413 418 409 414 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PKLR </italic></sub>
###xml 427 428 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 428 435 424 431 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 428 435 424 431 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NOS1AP </italic></sub>
###xml 519 520 511 512 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 652 653 644 645 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 653 658 645 650 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 653 658 645 650 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PKLR </italic></sub>
###xml 665 666 657 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 666 673 658 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 666 673 658 665 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NOS1AP </italic></sub>
###xml 754 755 742 743 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 879 880 867 868 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 880 885 868 873 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 880 885 868 873 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PKLR </italic></sub>
###xml 894 895 882 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 895 902 883 890 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 895 902 883 890 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NOS1AP </italic></sub>
###xml 985 986 969 970 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1055 1057 1039 1041 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1128 1129 1112 1113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="supplementary-material" rid="S1">1</xref>
###xml 1851 1871 1835 1855 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Helsinki Declaration</italic>
###xml 1969 1971 1953 1955 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 402 410 <span type="species:ncbi:9606">patients</span>
###xml 546 553 <span type="species:ncbi:9606">patient</span>
###xml 1496 1504 <span type="species:ncbi:9606">patients</span>
PKLR rs3020781 and NOS1AP rs7538490 were successfully genotyped in 16,801 and 16,913 Danes, respectively, involving four study groups 1) the population-based Inter99 cohort (ClinicalTrials.gov ID no: NCT00289237) (nPKLR = 5,962, nNOS1AP = 6,008), with an average age of 46 +/- 8 years and a mean BMI of 26.2 +/- 4.6 kg/m2, sampled at the Research Centre for Prevention and Health [22] 2) unrelated T2D patients (nPKLR = 1,873, nNOS1AP = 1,874), with an average age of 62 +/- 11 years and a mean BMI of 30.0 +/- 5.6 kg/m2, sampled through the out-patient clinic at Steno Diabetes Center 3) a population-based group of unrelated middle-aged individuals (nPKLR = 599, nNOS1AP = 596), with an average age of 59 +/- 8 years and a mean BMI of 26.5 +/- 4.2 kg/m2, examined at Steno Diabetes Center 4) the ADDITION Denmark screening study cohort (ClinicalTrials.gov ID no: NCT00237548) (nPKLR = 8,367, nNOS1AP = 8,435), with an average age of 60 +/- 7 years and a mean BMI of 28.6 +/- 4.9 kg/m2, sampled by Department of General Practice at University of Aarhus [23]. The different study groups are further described in Additional file 1. In study group 1 and 3 all non-diabetic individuals underwent a standard 75 g oral glucose tolerance test (OGTT) and only glucose-tolerant and normoglycaemic individuals were included as control subjects in the case-control study of T2D. Analyses of quantitative metabolic phenotypes were performed in the population-based Inter99 cohort exclusively, excluding T2D patients receiving pharmalogical treatment. Informed written consent was obtained from all individuals before participation. The studies were approved by the regional Ethical Committees (Ethics Committee, Copenhagen County for study group 1, 2 and 3 and Ethics Committee, Aarhus County for study group 4) and were in accordance with the principles of the Helsinki Declaration. T2D and normal glucose tolerance (NGT) were defined according to the World Health Organization [24].
###end p 18
###begin title 19
Biochemical and anthropometrical measurements
###end title 19
###begin p 20
###xml 100 102 100 102 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 103 105 103 105 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 479 481 479 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 705 706 705 706 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
###xml 783 785 783 785 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
###xml 786 788 786 788 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
In all study groups body weight and height were measured in light indoor clothes and without shoes [22,23]. In study groups 1 and 3 serum insulin and plasma glucose were measured at fasting and 30 and 120 minutes after an OGTT. Serum insulin levels excluding des(31,32)- and intact proinsulin were measured using the AutoDELFIA insulin kit (Perkin-Elmer, Wallac, Turku, Finland). Plasma glucose was analysed using a glucose oxidase method (Granutest; Merck, Darmstadt, Germany) [25]. The homeostasis model assessment of insulin resistance (HOMA-IR) was calculated as fasting plasma glucose (mmol/l) multiplied by fasting serum insulin (pmol/l) divided by 22.5. The BIGTT insulin sensitivity index (BIGTT-Si) and BIGTT acute insulin response (BIGTT-AIR) were calculated as described [26,27].
###end p 20
###begin title 21
Genotyping
###end title 21
###begin p 22
###xml 0 5 0 5 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 19 26 19 26 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 324 326 324 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
PKLR rs3020781 and NOS1AP rs7538490 were genotyped using Taqman allelic discrimination (KBioscience, Herts, UK). Discordances between 1,202 random duplicate samples were 0.1% and 0.2%, respectively, and the genotyping success rates were 96.3% and 96.8%, respectively. Both genotype groups obeyed Hardy-Weinberg equilibrium (p > 0.05).
###end p 22
###begin title 23
Statistical analysis
###end title 23
###begin p 24
###xml 277 282 277 282 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 324 331 324 331 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 610 612 610 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 619 620 619 620 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 1104 1106 1104 1106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1124 1126 1124 1126 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 820 828 <span type="species:ncbi:9606">patients</span>
Fisher's exact test was applied to examine differences in allele frequencies (AF) between affected and unaffected individuals. A general linear model was used to test quantitative metabolic variables for differences between genotype groups assuming an additive (Add) model for PKLR rs3020781, and a dominant (Dom) model for NOS1AP rs7538490. Values of plasma glucose, serum insulin, HOMA-IR and BIGTT-AIR were logarithmically transformed before statistical analysis to obtain normal distribution. Adjustment for sex, age and BMI was applied when appropriate. All analyses were performed in RGui version 2.5.0 [28], and p-values < 0.05 were considered significant. Statistical power was determined using the CaTS power calculator version 0.0.2. A test for homogeneity between the population-based Inter99 cohort, the T2D patients and the population-based sample from Steno Diabetes Center and the ADDITION Denmark screening study cohort, was performed by means of the Mantel-Haenszel method (fixed effects model) for both genotypes, revealing no significant heterogeneity between study groups (rs3020781: p = 0.8, rs7538490: p = 0.4).
###end p 24
###begin title 25
Results and discussion
###end title 25
###begin p 26
###xml 42 47 42 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 74 81 74 81 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 623 628 623 628 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 642 649 642 649 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 884 885 884 885 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 885 888 885 888 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AF </sub>
###xml 939 940 939 940 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 940 943 940 943 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AF </sub>
###xml 990 991 990 991 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 351 357 <span type="species:ncbi:9606">people</span>
###xml 807 815 <span type="species:ncbi:9606">patients</span>
The minor allele frequencies (MAF) of the PKLR rs3020781 C-allele and the NOS1AP rs7538490 T-allele were 26.2% and 28.0%, respectively, and comparable to the 32.5% and 29.7%, reported for the HapMap CEU population. Using the population-based Inter99 cohort as reference the prevalence of T2D is estimated to 6% in the Danish population of middle-aged people. Combining the four study samples, gives us a statistical power of 100% observing an association with T2D with a relative risk above 1.3, and a MAF as reported for the two variants assuming either an additive or a dominant model. The potential associations between PKLR rs3020781 and NOS1AP rs7538490 and T2D were evaluated in case-control studies including 8,410 and 8,447 individuals, respectively. No difference in allele frequencies between T2D patients and glucose-tolerant subjects were found for either SNP (rs3020781: pAF = 0.49, OR [95% CI] = 1.02 [0.96-1.10]; rs7538490: pAF = 0.84, OR [95% CI] = 0.99 [0.93-1.06]), Table 1.
###end p 26
###begin p 27
###xml 24 29 24 29 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 43 50 43 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
Case-control studies of PKLR rs3020781 and NOS1AP rs7538490 in relation to type 2 diabetes, overweight and obesity
###end p 27
###begin p 28
###xml 198 199 198 199 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 199 201 199 201 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AF</sub>
###xml 373 381 <span type="species:ncbi:9606">patients</span>
Data are number of individuals, divided into genotype groups (% in each group), and frequencies of the minor allele (MAF) in percentages. Fisher's exact test was used to compare allele frequencies (pAF). The odds ratios (OR) and 95% confidence interval (CI) are given for comparison of allele frequency. NGT: individuals with normal glucose tolerance, T2D: type 2 diabetic patients.
###end p 28
###begin p 29
###xml 116 117 116 117 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 154 156 154 156 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 173 174 171 172 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 201 202 197 198 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 389 394 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 417 418 413 414 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 418 421 414 417 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AF </sub>
###xml 470 471 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 471 474 467 470 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AF </sub>
###xml 522 529 518 525 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 552 553 548 549 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 553 556 549 552 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AF </sub>
###xml 605 606 601 602 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 606 609 602 605 <sub xmlns:xlink="http://www.w3.org/1999/xlink">AF </sub>
###xml 656 657 652 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 289 297 <span type="species:ncbi:9606">patients</span>
###xml 799 807 <span type="species:ncbi:9606">patients</span>
Case-control studies comparing allele frequencies between body mass index (BMI) defined normal weight (BMI < 25 kg/m2) individuals and overweight (25 kg/m2 </= BMI < 30 kg/m2) or obese (BMI >/= 30 kg/m2) individuals, respectively, were performed in the combined study sample including T2D patients. No statistically significant association with overweight or obesity were demonstrated for PKLR rs3020781 (overweight: pAF = 0.49, OR [95% CI] = 0.98 [0.92-1.04]; obesity: pAF = 0.81, OR [95% CI] = 0.99 [0.93-1.06]) nor for NOS1AP rs7538490 (overweight: pAF = 0.48, OR [95% CI] = 0.95 [0.83-1.09]; obesity: pAF = 0.68, OR [95% CI] = 0.99 [0.93-1.05]), Table 1. As pharmacological treatment can influence on BMI, we additionally performed case-control studies of overweight and obesity considering T2D patients and treatment-naive indviduals separately, however, neither variant showed association with overweight or obesity when stratifying according to glucose tolerance status (data not shown).
###end p 29
###begin p 30
###xml 29 34 29 34 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 48 55 48 55 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 446 447 446 447 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 691 692 691 692 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 692 697 692 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 692 697 692 697 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>PKLR </italic></sub>
###xml 706 707 706 707 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 707 714 707 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 707 714 707 714 <sub xmlns:xlink="http://www.w3.org/1999/xlink"><italic>NOS1AP </italic></sub>
###xml 175 181 <span type="species:ncbi:9606">people</span>
Furthermore, we investigated PKLR rs3020781 and NOS1AP rs7538490 for influence on diabetes-related quantitative metabolic phenotypes in 5,590 and 5,630 treatment-naive Danish people from the population-based Inter99 cohort, respectively. No association with plasma glucose or serum insulin levels at fasting, 30 or 120 min during an OGTT or with OGTT-derived surrogate indices of insulin sensitivity or beta-cell function was demonstrated, Table 2. To evaluate the effect of the variants in individuals without impaired blood glucose regulation, analyses of quantitative metabolic phenotypes were conducted in the population-based Inter99 cohort including only glucose-tolerant individuals (nPKLR = 4,248, nNOS1AP = 4,269). However, no significant differences in genotype distribution of the two SNPs were demonstrated (data not shown).
###end p 30
###begin p 31
###xml 156 161 156 161 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 188 195 188 195 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
Quantitative metabolic characteristics of 5,590 and 5,630 treatment-naive individuals from the population-based Inter99 cohort, stratified according to the PKLR rs3020781 genotype and the NOS1AP rs7538490 genotype, respectively
###end p 31
###begin p 32
###xml 242 247 240 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 316 323 314 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 378 379 376 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p</italic>
###xml 530 532 528 530 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 680 682 678 680 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i </sub>
###xml 726 728 724 726 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B26">26</xref>
Data are means +/- standard deviation or median (interquartile range). Values of plasma glucose, serum insulin, HOMA-IR and BIGTT-AIR were logarithmically transformed before statistical analysis to obtain normal distribution. All analyses of PKLR rs3020781 were made using an additive model (Add), while analyses of NOS1AP rs7539480 were made using a dominant model. Calculated p-values were adjusted for age and sex for BMI measures, for sex, age and BMI for serum insulin, plasma glucose and HOMA-IR, and for age for the BIGTT-Si and BIGTT-AIR index. HOMA-IR was calculated as fasting plasma glucose (mmol/l) multiplied by fasting serum insulin (pmol/l) divided by 22.5. BIGTT-Si and BIGTT-AIR were calculated as described [26].
###end p 32
###begin p 33
Despite successful identification of several T2D susceptible genes only a small percentage of T2D heritability is explained, thus, more T2D genes are to be found.
###end p 33
###begin p 34
###xml 302 307 302 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 357 363 357 363 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP</italic>
###xml 609 614 609 614 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 618 624 618 624 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP</italic>
Originally two clusters of SNPs located within the T2D linkage peak were identified by The International Type 2 Diabetes 1q Consortium to associate with T2D among a total of 5,285 SNPs tagging the linkage peak. The first cluster of 9 SNPs were located in a linkage disequilibrium (LD) region including PKLR while the second cluster of 4 SNPs resided within NOS1AP. Replication of such potential associations, in statistically well-powered studies, is essential to substantiate the initial findings. Therefore, we aimed specifically at replicating the strongest associations in the two clusters of SNPs within PKLR and NOS1AP, which are rs3020781 and rs7538490, respectively. However, we did not show any association with T2D for either of the two variants, despite having the statistical power to detect the reported effect sizes. Neither did we find an association with pertinent metabolic phenotypes, which could indicate an impaired blood glucose regulation ultimately leading to T2D.
###end p 34
###begin p 35
###xml 117 122 117 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 126 133 126 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 188 193 188 193 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 307 311 307 311 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR</italic>
###xml 412 414 412 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 785 792 785 792 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
From our studies we can exclude rs3020781 and rs7538490 as T2D susceptibility variants in the Danish population, but PKLR and NOS1AP may still represent true T2D susceptibility loci. That PKLR represents a true T2D candidate gene, is supported by a study analysing two SNPs (rs1052176 and rs1052177) within PKLR, both showing association with T2D and both being in perfect LD with rs3020781 according to HapMap [21]. HapMap further outlined that rs3020781 is located at the border of a LD block near a recombination hotspot. Therefore, if the LD pattern is slightly shifted in our population, compared to the populations in which association is observed, rs3020781 may fail as a marker for the functional variant. Similar may be true for rs7538490, as LD is sparse in the region where NOS1AP is located. Thus, different LD patterns could explain the lack of association between rs3020781 and rs7538490 and T2D in our population.
###end p 35
###begin p 36
###xml 115 120 115 120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 124 130 124 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP</italic>
In regards to the identification of T2D susceptibility genes, the linkage analysis, used for the identification of PKLR and NOS1AP, has been less successful due to inconsistent replication.
###end p 36
###begin p 37
###xml 155 157 155 157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 158 160 158 160 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 287 289 287 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B37">37</xref>
###xml 395 400 395 400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 404 411 404 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 507 509 507 509 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 538 543 538 543 <italic xmlns:xlink="http://www.w3.org/1999/xlink">PKLR </italic>
###xml 666 673 666 673 <italic xmlns:xlink="http://www.w3.org/1999/xlink">NOS1AP </italic>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
However, genome-wide association (GWA) studies have added to progress in finding common T2D susceptible gene variants with modest impact on diabetes risk [29-34], with the identification of non-obvious biological candidate genes and where replication have been predominantly successful [35-37]. We have investigated results of available data from GWA studies in web-based databases, but neither PKLR nor NOS1AP were among the high priority candidate genes as estimated from genome-wide significance levels [29,30]. Two markers in LD with PKLR rs3020781 were available in the public GWA data, however, none of these associated with T2D. No markers were available for NOS1AP rs7538490 [29]. The lack of association could either be due to small effect sizes, or the possibility that the variants represent false positive findings, thus explaining our failure to demonstrate an association.
###end p 37
###begin title 38
Conclusion
###end title 38
###begin p 39
In statistically well-powered case-control studies and in studies of pertinent quantitative phenotypes we failed to validate the proposed association of the C-allele of rs3020781 and the T-allele of rs7538490 with T2D or intermediate phenotypes.
###end p 39
###begin title 40
Abbreviations
###end title 40
###begin p 41
###xml 91 92 91 92 <sub xmlns:xlink="http://www.w3.org/1999/xlink">i</sub>
Add: additive model; AF: allele frequency; BIGTT-AIR: BIGTT acute insulin response; BIGTT-Si: BIGTT insulin sensitivity index; BMI: body mass index; CAPON: nitric oxide synthase 1 (neuronal) adaptor protein; CI: confidence interval; Dom: dominant model; GWA: genome-wide association; HOMA-IR: homeostasis model assessment of insulin resistance; LD: linkage disequilibrium; MAF: minor allele frequency; NGT: normal glucose tolerance; OGTT: oral glucose tolerance test; OR: odds ratio; SNP: single-nucleotide polymorphism; T2D: type 2 diabetes
###end p 41
###begin title 42
Competing interests
###end title 42
###begin p 43
KBJ and OP hold stock in Novo Nordisk and have received lecture fees from pharmaceutical companies. All other authors declare that there is no competing interest associated with this manuscript.
###end p 43
###begin title 44
Authors' contributions
###end title 44
###begin p 45
The original hypothesis was conceived by CHA and MSM and approved by OP and TH. Detail planning of analyses and study design was performed by CHA, MSM and approved by OP and TH. TJ, KBJ, TL, AS, OP and TH contributed to the epidemiological part of the recruitment of study populations. CHA, MSM, KA, LH, OP and TH contributed to the preparation of study populations for statistical analyses. Statistical analyses were performed by CHA and MSM. All authors contributed the interpretation of data. The first manuscript was written by CHA and MSM and the final draft was finalised by CHA, MSM, OP and TH. All authors revised the manuscript and contributed to the discussion of the results.
###end p 45
###begin title 46
Acknowledgements
###end title 46
###begin p 47
The authors wish to thank A. Forman, I.-L. Wantzin and M. Stendal for technical assistance and G. Lademann for secretarial support. The study was supported by grants from the Danish Health Research Council, The European Union (EUGENE-2, grant no LSHM-CT-2004-512013), the FOOD Study Group/the Danish Ministry of Food, Agriculture and Fisheries and Ministry of Family and Consumer Affairs (grant no. 2101-05-0044), Novo Nordisk A/S Research & Development Corporate Research Affairs, the Danish Ministry of Science Technology and Innovation, the Faculty of Health Sciences of Aarhus University, the Danish Clinical Intervention Research Academy, and the Danish Diabetes Association. The ADDITION trial was supported by the National Health Services in the counties of Copenhagen, Aarhus, Ringkobing, Ribe and South Jutland in Denmark, Danish Research Foundation for General Practice, Danish Centre for Evaluation and Health Technology Assessment, The diabetes fund of the National Board of Health, The Danish Medical Research Council, The Aarhus University Research Foundation and Novo Nordisk Foundation. Furthermore the ADDITION trial has been given unrestricted grants from Novo Nordisk A/S, Novo Nordisk Scandinavia AB, ASTRA Denmark, Pfizer Denmark, GlaxoSmithKline Pharma Denmark, SERVIER Denmark A/S and HemoCue Denmark A/S.
###end p 47
###begin title 48
Pre-publication history
###end title 48
###begin p 49
The pre-publication history for this paper can be accessed here:
###end p 49
###begin p 50

###end p 50
###begin title 51
Supplementary Material
###end title 51
###begin title 52
Additional file 1
###end title 52
###begin p 53
###xml 0 22 0 22 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Supplementary table 1.</bold>
Supplementary table 1.
###end p 53
###begin p 54
Click here for file
###end p 54
###begin title 55
Footnotes
###end title 55
###begin p 56
1 EASD 2007Abstract no. 0169 () ; Prokopenko I, Zeggini E, Rayner NW, Groves CJ, Hanson RL, Mitchell BD et al.. High-density association mapping and coprehensive tagging of the type 2 diabetes linkage region on chromosome 1q in 4 European populations.
###end p 56
###begin article-title 57
The search for type 2 diabetes susceptibility loci: the chromosome 1q story
###end article-title 57
###begin article-title 58
Linkage and association mapping of a chromosome 1q21-q24 type 2 diabetes susceptibility locus in northern European Caucasians
###end article-title 58
###begin article-title 59
A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians
###end article-title 59
###begin article-title 60
An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians
###end article-title 60
###begin article-title 61
Family and genetic studies of indices of insulin sensitivity and insulin secretion in Pima Indians
###end article-title 61
###begin article-title 62
Genome-wide and fine-mapping linkage studies of type 2 diabetes and glucose traits in the Old Order Amish: evidence for a new diabetes locus on chromosome 14q11 and confirmation of a locus on chromosome 1q21-q24
###end article-title 62
###begin article-title 63
Linkage of the metabolic syndrome to 1q23-q31 in Hispanic families: the Insulin Resistance Atherosclerosis Study Family Study
###end article-title 63
###begin article-title 64
A genome-wide scan for loci linked to plasma levels of glucose and HbA(1c) in a community-based sample of Caucasian pedigrees: The Framingham Offspring Study
###end article-title 64
###begin article-title 65
Genome-wide scan for type 2 diabetes loci in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25
###end article-title 65
###begin article-title 66
Genome-wide scan for metabolic syndrome and related quantitative traits in Hong Kong Chinese and confirmation of a susceptibility locus on chromosome 1q21-q25
###end article-title 66
###begin article-title 67
Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24
###end article-title 67
###begin article-title 68
A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q
###end article-title 68
###begin article-title 69
Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24
###end article-title 69
###begin article-title 70
An autosomal genomic scan for loci linked to type 2 diabetes in northern Han Chinese
###end article-title 70
###begin article-title 71
Expression of liver type pyruvate kinase in insulinoma cells: involvement of LF-B1 (HNF1)
###end article-title 71
###begin article-title 72
###xml 90 93 <span type="species:ncbi:10116">rat</span>
Characterization and purification of carbohydrate response element-binding protein of the rat L-type pyruvate kinase gene promoter
###end article-title 72
###begin article-title 73
###xml 23 28 <span type="species:ncbi:9606">human</span>
Molecular targets of a human HNF1 alpha mutation responsible for pancreatic beta-cell dysfunction
###end article-title 73
###begin article-title 74
###xml 31 35 <span type="species:ncbi:10090|species:ncbi:10095">mice</span>
Loss of HNF-1alpha function in mice leads to abnormal expression of genes involved in pancreatic islet development and metabolism
###end article-title 74
###begin article-title 75
CAPON: a protein associated with neuronal nitric oxide synthase that regulates its interactions with PSD95
###end article-title 75
###begin article-title 76
Liver pyruvate kinase polymorphisms are associated with type 2 diabetes in northern European Caucasians
###end article-title 76
###begin article-title 77
Type 2 diabetes susceptibility genes on chromosome 1q21-24
###end article-title 77
###begin article-title 78
A randomized non-pharmacological intervention study for prevention of ischaemic heart disease: baseline results Inter99
###end article-title 78
###begin article-title 79
###xml 138 144 <span type="species:ncbi:9606">people</span>
The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening
###end article-title 79
###begin article-title 80
Part 1: Diagnosis and Classification of Diabetes Mellitus
###end article-title 80
###begin article-title 81
Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study
###end article-title 81
###begin article-title 82
The BIGTT test: a novel test for simultaneous measurement of pancreatic beta-cell function, insulin sensitivity, and glucose tolerance
###end article-title 82
###begin article-title 83
Are there common genetic and environmental factors behind the endophenotypes associated with the metabolic syndrome?
###end article-title 83
###begin article-title 84
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels
###end article-title 84
###begin article-title 85
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
###end article-title 85
###begin article-title 86
A genome-wide association study identifies novel risk loci for type 2 diabetes
###end article-title 86
###begin article-title 87
A variant in CDKAL1 influences insulin response and risk of type 2 diabetes
###end article-title 87
###begin article-title 88
A genome-wide association study of type 2 diabetes in Finns detects multiple susceptibility variants
###end article-title 88
###begin article-title 89
Replication of genome-wide association signals in UK samples reveals risk loci for type 2 diabetes
###end article-title 89
###begin article-title 90
Studies of association of variants near the HHEX, CDKN2A/B, and IGF2BP2 genes with type 2 diabetes and impaired insulin release in 10,705 Danish subjects: validation and extension of genome-wide association studies
###end article-title 90
###begin article-title 91
The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes
###end article-title 91
###begin article-title 92
Low physical activity accentuates the effect of the FTO rs9939609 polymorphism on body fat accumulation
###end article-title 92
###begin article-title 93
High-density association mapping and coprehensive tagging of the type 2 diabetes linkage region on chromosome 1q in 4 European populations
###end article-title 93

